Amicus Therapeutics, Inc. (0HF9.L)
USD 6.64
(3.91%)
USD 6.64
(3.91%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 427.65 Million USD | -13.62% |
| 2022 | 495.06 Million USD | 5.12% |
| 2021 | 470.96 Million USD | -0.58% |
| 2020 | 473.69 Million USD | 2.75% |
| 2019 | 461.01 Million USD | 14.59% |
| 2018 | 402.31 Million USD | 66.54% |
| 2017 | 241.57 Million USD | 34.82% |
| 2016 | 179.18 Million USD | 42.16% |
| 2015 | 126.04 Million USD | 80.35% |
| 2014 | 69.88 Million USD | 11.72% |
| 2013 | 62.55 Million USD | -12.32% |
| 2012 | 71.34 Million USD | -1.35% |
| 2011 | 72.32 Million USD | 27.42% |
| 2010 | 56.76 Million USD | -19.13% |
| 2009 | 70.18 Million USD | 19.11% |
| 2008 | 58.92 Million USD | 23.82% |
| 2007 | 47.58 Million USD | 1.56% |
| 2006 | 46.85 Million USD | 124.95% |
| 2005 | 20.83 Million USD | 336.53% |
| 2004 | -8.8 Million USD | -233.44% |
| 2003 | 6.6 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 98.25 Million USD | -15.55% |
| 2024 Q1 | 116.35 Million USD | 10.54% |
| 2023 Q4 | 105.26 Million USD | -1.02% |
| 2023 Q1 | 116.71 Million USD | -2.3% |
| 2023 FY | 427.65 Million USD | -13.62% |
| 2023 Q2 | 102.77 Million USD | -11.94% |
| 2023 Q3 | 106.35 Million USD | 3.48% |
| 2022 Q4 | 119.45 Million USD | 17.66% |
| 2022 FY | 495.06 Million USD | 5.12% |
| 2022 Q1 | 141.04 Million USD | -2.54% |
| 2022 Q2 | 133.03 Million USD | -5.68% |
| 2022 Q3 | 101.52 Million USD | -23.68% |
| 2021 Q2 | 106.84 Million USD | -4.98% |
| 2021 Q4 | 144.71 Million USD | 35.3% |
| 2021 FY | 470.96 Million USD | -0.58% |
| 2021 Q1 | 112.44 Million USD | -10.42% |
| 2021 Q3 | 106.96 Million USD | 0.11% |
| 2020 Q3 | 110.76 Million USD | 4.19% |
| 2020 Q1 | 131.09 Million USD | -4.12% |
| 2020 Q2 | 106.3 Million USD | -18.91% |
| 2020 FY | 473.69 Million USD | 2.75% |
| 2020 Q4 | 125.52 Million USD | 13.33% |
| 2019 Q2 | 114.71 Million USD | 4.39% |
| 2019 Q4 | 136.72 Million USD | 37.15% |
| 2019 Q3 | 99.68 Million USD | -13.1% |
| 2019 Q1 | 109.88 Million USD | 13.07% |
| 2019 FY | 461.01 Million USD | 14.59% |
| 2018 Q2 | 64.8 Million USD | -6.3% |
| 2018 Q4 | 97.18 Million USD | -43.22% |
| 2018 FY | 402.31 Million USD | 66.54% |
| 2018 Q1 | 69.16 Million USD | -8.39% |
| 2018 Q3 | 171.16 Million USD | 164.13% |
| 2017 Q1 | 50.83 Million USD | 1.22% |
| 2017 FY | 241.57 Million USD | 34.82% |
| 2017 Q4 | 75.49 Million USD | 19.57% |
| 2017 Q3 | 63.13 Million USD | 21.17% |
| 2017 Q2 | 52.1 Million USD | 2.51% |
| 2016 Q2 | 38.34 Million USD | -3.65% |
| 2016 FY | 179.18 Million USD | 42.16% |
| 2016 Q4 | 50.21 Million USD | -1.19% |
| 2016 Q3 | 50.82 Million USD | 32.53% |
| 2016 Q1 | 39.79 Million USD | -1.47% |
| 2015 FY | 126.04 Million USD | 80.35% |
| 2015 Q4 | 40.39 Million USD | 9.95% |
| 2015 Q3 | 36.73 Million USD | 42.04% |
| 2015 Q2 | 25.86 Million USD | 12.22% |
| 2015 Q1 | 23.04 Million USD | 7.27% |
| 2014 Q2 | 15.12 Million USD | -2.91% |
| 2014 Q3 | 17.69 Million USD | 16.97% |
| 2014 Q1 | 15.58 Million USD | 10.29% |
| 2014 FY | 69.88 Million USD | 11.72% |
| 2014 Q4 | 21.48 Million USD | 21.43% |
| 2013 Q2 | 16 Million USD | -7.22% |
| 2013 Q4 | 14.12 Million USD | -6.91% |
| 2013 Q1 | 17.25 Million USD | 8.34% |
| 2013 Q3 | 15.17 Million USD | -5.19% |
| 2013 FY | 62.55 Million USD | -12.32% |
| 2012 Q2 | 19.98 Million USD | 7.91% |
| 2012 Q4 | 15.92 Million USD | -5.87% |
| 2012 Q3 | 16.91 Million USD | -15.35% |
| 2012 Q1 | 18.51 Million USD | -0.76% |
| 2012 FY | 71.34 Million USD | -1.35% |
| 2011 Q4 | 18.66 Million USD | -1.44% |
| 2011 Q3 | 18.93 Million USD | 0.9% |
| 2011 Q1 | 15.96 Million USD | -8.55% |
| 2011 Q2 | 18.76 Million USD | 17.53% |
| 2011 FY | 72.32 Million USD | 27.42% |
| 2010 Q4 | 17.45 Million USD | 31.61% |
| 2010 FY | 56.76 Million USD | -19.13% |
| 2010 Q3 | 13.26 Million USD | 4.56% |
| 2010 Q2 | 12.68 Million USD | -4.97% |
| 2010 Q1 | 13.35 Million USD | -11.07% |
| 2009 FY | 70.18 Million USD | 19.11% |
| 2009 Q4 | 15.01 Million USD | -18.36% |
| 2009 Q3 | 18.38 Million USD | -4.29% |
| 2009 Q2 | 19.21 Million USD | 9.31% |
| 2009 Q1 | 17.57 Million USD | -8.57% |
| 2008 Q1 | 12.44 Million USD | -18.46% |
| 2008 FY | 58.92 Million USD | 23.82% |
| 2008 Q3 | 12.95 Million USD | -9.41% |
| 2008 Q2 | 14.29 Million USD | 14.86% |
| 2008 Q4 | 19.22 Million USD | 48.4% |
| 2007 Q3 | 11.8 Million USD | 14.8% |
| 2007 Q1 | 10.23 Million USD | 188.31% |
| 2007 Q4 | 15.26 Million USD | 29.32% |
| 2007 FY | 47.58 Million USD | 1.56% |
| 2007 Q2 | 10.28 Million USD | 0.51% |
| 2006 FY | 46.85 Million USD | 124.95% |
| 2006 Q2 | -11.58 Million USD | 0.0% |
| 2006 Q1 | -11.58 Million USD | -132.05% |
| 2006 Q4 | -11.58 Million USD | 0.0% |
| 2006 Q3 | -11.58 Million USD | 0.0% |
| 2005 Q1 | -4.99 Million USD | 0.0% |
| 2005 Q3 | -4.99 Million USD | 0.0% |
| 2005 Q2 | -4.99 Million USD | 0.0% |
| 2005 Q4 | -4.99 Million USD | 0.0% |
| 2005 FY | 20.83 Million USD | 336.53% |
| 2004 FY | -8.8 Million USD | -233.44% |
| 2003 FY | 6.6 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 95.829% |
| Dynavax Technologies Corporation | 219.14 Million USD | -95.145% |
| Illumina, Inc. | 3.81 Billion USD | 88.784% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 79.169% |
| Biogen Inc. | 5.2 Billion USD | 91.784% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 5.176% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 60.744% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 68.574% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 19.16% |
| Waters Corporation | 943.51 Million USD | 54.675% |
| Perrigo Company plc | 1.52 Billion USD | 72.022% |
| uniQure N.V. | 285.08 Million USD | -50.008% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -4.61% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -55.119% |
| bluebird bio, Inc. | 240.23 Million USD | -78.016% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -200.184% |
| Imunon, Inc. | 21.03 Million USD | -1933.487% |
| Myriad Genetics, Inc. | 600.1 Million USD | 28.737% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 73.213% |
| Nektar Therapeutics | 190.9 Million USD | -124.015% |
| Editas Medicine, Inc. | 247.3 Million USD | -72.925% |
| Verastem, Inc. | 92.08 Million USD | -364.414% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 98.947% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -2974.493% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -254.435% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -857.42% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 75.511% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -87.008% |
| Evolus, Inc. | 189.75 Million USD | -125.365% |
| Adicet Bio, Inc. | 152.03 Million USD | -181.279% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -3422.37% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 84.81% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -57.284% |
| FibroGen, Inc. | 398.11 Million USD | -7.42% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 79.78% |
| OPKO Health, Inc. | 574.68 Million USD | 25.585% |
| Homology Medicines, Inc. | 9.87 Million USD | -4230.643% |
| Geron Corporation | 70.44 Million USD | -507.105% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 76.242% |
| Exelixis, Inc. | 1.58 Billion USD | 73.049% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -324.143% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -667.004% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 22.466% |
| Zoetis Inc. | 2.76 Billion USD | 84.533% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 10.225% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -781.718% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 91.044% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -992.256% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 45.144% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -16.017% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -42.875% |
| Blueprint Medicines Corporation | 722.86 Million USD | 40.839% |
| Insmed Incorporated | 949.26 Million USD | 54.949% |
| TG Therapeutics, Inc. | 198.47 Million USD | -115.468% |
| Incyte Corporation | 1.19 Billion USD | 64.078% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 59.037% |